Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 801–900 of 1,000
Mangla, A., Paydary, K., Liu, J., Mbachi, C. U., Yim, B. T., & Lad, T. E. (2018) · Hematological Oncology · doi:10.1002/hon.2535 · Cited by 8
Olson, T. L., Zhang, S., Labban, D., Kaschner, E. K., Aceves, M., Iyer, S., Meza-Aguilar, J. D., Zook, J. D., Chun, E., Craciunescu, F. M., et al. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.105890 · Cited by 8
Self-citationManagement of Cancer Therapy–Related Cardiac Dysfunction: A Case-Based Review
Mallidi, J., Baylis, R. A., & Song, E. J. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.08.029 · Cited by 8
Orphan drug approvals of 2015: Europe and the United States
Norman, P. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1167595 · Cited by 8
“Although approved by the FDA in 2012 for the treatment of multiple myeloma, European filing was only submitted in January 2015 based on the ASPIRE study.[12] Onyx (now Amgen) had originally intended to file in 2013 based on the outcome of the FOCUS study, which compared carfilzomib with best standard of care, but the…”
The Role of Carfilzomib in Treatment of Newly Diagnosed Multiple Myeloma
Strifler, S., & Knop, S. T. (2018) · Future Oncology · doi:10.2217/fon-2018-0040 · Cited by 8
Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
Paner, A., Okwuosa, T. M., Richardson, K. J., & Libby, E. N. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1538777 · Cited by 8
“patients with RRMM were randomized to either KRd for 18 months followed by Rd or Rd [12].”
BackgroundMethodInfluentialMechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Nooka, A. K., & Lonial, S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000354 · Cited by 8
on behalf of the European Myeloma Network, Caballero‐Velázquez, T., Calderón‐Cabrera, C., López‐Corral, L., Puig, N., Márquez-Malaver, F. J., Pérez‐López, E., García-Calderón, C. B., Rosso-Fernández, C. M., Caballero, D. M., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0670-6 · Cited by 8
Self-citationCereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Huang, P. A., Beedie, S., Chau, C. H., Venzon, D. J., Gere, S., Kazandjian, D. G., Korde, N., Mailankody, S., Landgren, O., & Figg, W. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-51446-9 · Cited by 9
The safety of current and emerging therapies for multiple myeloma
Nadeem, O., & Anderson, K. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733968 · Cited by 8
Kadikova, R. N., Ramazanov, I. R., Gabdullin, A. M., Mozgovoj, O. S., & Dzhemilev, U. M. (2020) · RSC Advances · doi:10.1039/d0ra02677h · Cited by 8
Steinmetz, T., Singh, M., Lebioda, A., Gonzalez‐McQuire, S., Rieth, A., Schoehl, M., & Poenisch, W. (2020) · Oncology Research and Treatment · doi:10.1159/000509018 · Cited by 8
Calafiore, V., Giamporcaro, S., Conticello, C., Romano, A., Parisi, M. S., Giuffrida, G., Tibullo, D., Raimondo, F. D., & Signorelli, S. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092876 · Cited by 8
“6%), despite the mandatory use of thromboprophylaxis [45].”
BackgroundWeisel, K. C., Mateos, M., Gay, F., Delforge, M., Cook, G., Szabó, Z. R., Desgraz, R., DeCosta, L., & Moreau, P. (2020) · Leukemia · doi:10.1038/s41375-020-01049-5 · Cited by 8
Self-citationMaresh, M. E., Salazar‐Chaparro, A. F., & Trader, D. J. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0288 · Cited by 9
“The success of using proteasome inhibitors to treat blood cancers is reflected by the US FDAapproved drug bortezomib and its second-generation counterpart, carfilzomib (Figure 3) [36,37].”
BackgroundKambhampati, S., Fakhri, B., Ai, W. Z., Kaplan, L. D., Tuscano, J. M., Wieduwilt, M. J., Sudhindra, A., Cavallone, E., Reiner, J., Aoun, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.020 · Cited by 8
Shen, X., Wu, C., Lei, M., Yan, Q., Zhang, H., Zhang, L., Wang, X., Yang, Y., Li, J., Zhu, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03701-z · Cited by 8
Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma
Kwong, Y. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2392-1 · Cited by 8
Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo
Joao, C. M., Bergantim, R., Santos, J., Afonso, C., Bernardo, P. A. V. D. C., Coelho, H. G. B., Costa, C. M. A., Esteves, G. V., de Freitas, J. G., Gerivaz, R., et al. (2023) · Acta Médica Portuguesa · doi:10.20344/amp.19037 · Cited by 10
Liu, Y., He, X., Sui, Y., Yu, R., & Xu, G. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.06.044 · Cited by 8
“Frontline treatments for this disease include the use of steroids such as dexamethasone, proteasome inhibitors such as bortezomib and carfilzomib, immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide, or their combination [2,3].”
BackgroundMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Self-citationGarderet, L., Cook, G., Auner, H. W., Bruno, B., Lokhorst, H. M., Pérez‐Simón, J. A., Sahebi, F., Scheid, C., Morris, C., van Biezen, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228926 · Cited by 8
Iida, S., Watanabe, T., Matsumoto, M., Suzuki, K., Sunami, K., Ishida, T., Ando, K., Chou, T., Ozaki, S., Taniwaki, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14139 · Cited by 8
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
Saburi, M., Ogata, M., Soga, Y., Kondo, Y., Kurimoto, R., Itani, K., Kohno, K., Uchida, H., & Nakayama, T. (2020) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.19031 · Cited by 8
Basic, E., Kappel, M., Misra, A., Sellner, L., Ratsch, B. A., & Ostwald, D. A. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01219-3 · Cited by 8
Maouche, N., Kishore, B., Jenner, M. W., Boyd, K. D., Bhatti, Z., Bird, S. A., Chander, G., Robinson, R., Vallance, G. D., Offer, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864355 · Cited by 8
“used across recent clinical trials [4].”
Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025
Voorhees, P. M., Jakubowiak, A. J., Kumar, S. K., Kanapuru, B., Baines, A. C., Bhatnagar, V., Ershler, R., Theoret, M. R., Gormley, N. J., & Pazdur, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1069 · Cited by 8
“Precision medicine strategy The availability of targeted agents against specific mutations and a better understanding of the mutation spectrum in multiple myeloma sets the stage for precision medicine trials, but trial design remains a challenge (5).”
BackgroundSelf-citationJulio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 10
Novellis, D. D., Scala, P., Giudice, V., & Selleri, C. (2025) · Cells · doi:10.3390/cells14110776 · Cited by 7
“In lenalidomide-sensitive patients, triplet regimens, such as dara-RD, KRD, elotuzumab-RD, or ixazomib-RD, have shown clinical efficacy [91–95], although HRMM patients display inferior PFS and response durability compared to standard-risk cohorts.”
Lee, J. H., Choi, J., Min, C., Park, S., Jo, J., Lee, Y. J., Kim, J. S., Eom, H., Jung, J., Moon, J. H., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285534 · Cited by 7
Zolnowski, D., Karp, S., Warncke, P., Zinn, J., Pannach, M., Herbst, R., Hänel, A., Morgner, A., Ibach, S., Fricke, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05993-y · Cited by 7
“In addition, STP was often poorly or not represented in large randomized myeloma studies (Dimopoulos et al. 2017; Lonial et al. 2015b; Moreau et al. 2016 , 2019; Palumbo et al. 2016 ; San-Miguel et al. 2014 ; Stewart et al. 2015).”
BackgroundCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
“While the ASPIRE trial excluded bortezomib refractory individuals, subsequent findings from the A.R.R.O.W and A.R.R.O.W.2 trials have demonstrated that carfilzomib can be effectively utilized in this population [53,54,63,64].”
Lu, J., Hou, J., Liu, K., Parmar, S., de la Fuente, A., Andersson, B., Yan, C., Zhou, D., Tan, D. C. L., Ritchie, D., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1135434 · Cited by 7
“While carfilzomib, a proteasome inhibitor, combined with len-dex is a category 1 recommendation in the relapsed setting, its promise is only now being realized.[11,12] Since the undertaking of this survey, updated results from the ASPIRE and ENDEAVOR demonstrating the efficacy of carfilzomib in the relapsed setting ha…”
ResultSelf-citationBaertsch, M., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M. S., Hose, D., Wuchter, P., Ho, A. D., Jauch, A. S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2321-2 · Cited by 7
Richez, V., Gruchet, C., Guidez, S., Fouquet, G., Azaïs, I., Durand, G., Javaugue, V., Brigaud, A., Plasse, F., Diolez, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25327 · Cited by 7
Jackson, S., Agbana, P., Kim, K., & Bae, Y. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.09.022 · Cited by 7
Davies, F. E., Leleu, X. P., Vogel, P., Dhanasiri, S., Nouveau, P. L., & Weisel, K. C. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.07.010 · Cited by 7
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 9
Serum Free Light Chain (FLC) Analysis: A Guiding Light in Monoclonal Gammopathy Management
Jenner, E. L., Evans, J. A. R., & Harding, S. J. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.021352 · Cited by 7
Mele, G., & Pastore, D. (2018) · Case Reports in Hematology · doi:10.1155/2018/2312430 · Cited by 7
Takakuwa, T., Otomaru, I., Araki, T., Miura, A., Fujitani, Y., Mochizuki, Y., Miyagi, Y., Senzaki, H., & Yamamura, R. (2019) · Case Reports in Hematology · doi:10.1155/2019/1816287 · Cited by 7
Limited treatment options in refractory multiple myeloma: promising therapeutic developments
Oriol, A., Abril, L., Ibarra, G., & Senín, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1708721 · Cited by 8
Self-citationDhakal, B., Narra, R. K., Giri, S., Szabó, A., Smunt, T. L., Ghose, S., Pathak, L. K., Aryal, M. R., Hamadani, M., Chhabra, S., et al. (2020) · Cancer · doi:10.1002/cncr.32831 · Cited by 7
Acute coronary syndromes in cancer patients
Bisceglia, I., Canale, M. L., Lestuzzi, C., Parrini, I., Russo, G., Colivicchi, F., Gabrielli, D., Gulizia, M. M., & Iliescu, C. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000993 · Cited by 7
Repositioning the Repurposed Drug, a Structural Study of Thalidomide Analogs
Rahmat, M., Sklavenitis‐Pistofidis, R., & Ghobrial, I. M. (2019) · The Hematologist · doi:10.1182/hem.v16.3.9556 · Cited by 7
Old and new generation immunomodulatory drugs in multiple myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04125-7 · Cited by 8
Reece, D. E., Masih‐Khan, E., Atenafu, E. G., Jimenez-Zepeda, V. H., McCurdy, A. B. R., Song, K., LeBlanc, R., Sébag, M., White, D. J., Cherniawsky, H. M., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13678 · Cited by 7
“CYBOR- D/P (40); RVD (1); VMP (4); VC (1); VD/P (10); Bortezomib (2) Other- proteasome inhibitor, 12 (13.8”
InfluentialMechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma
Proskuriakova, E., Jada, K., Djossi, S. K., Khedr, A., Neupane, B., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.15943 · Cited by 9
Engelhardt, M. M., Szymaniak-Vits, M., Ajayi, S., Dold, S. M., Müller, S. J., Scheubeck, S., & Wäsch, R. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_13 · Cited by 7
Kawasaki, A., Murakami, H., Chou, T., Matsushita, M., & Kizaki, M. (2022) · Future Oncology · doi:10.2217/fon-2022-0259 · Cited by 7
Mangiacavalli, S., Cartia, C. S., Galli, M., Pezzatti, S., Belotti, A., Fazio, F., Mina, R., Marcatti, M., Cafro, A. M., Zambello, R., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281342 · Cited by 7
“Anyway, since in our study patients addressed to KRd are on average younger, grade 3 and 4 toxicity, in particular cardiovascular AEs, were superimposable to ASPIRE and to previously RWD.(6, 18, 19) In conclusion, our real-world data depict an evolving pattern in the daily management of lenalidomide sensitive MM patie…”
BackgroundResultInfluentialHjazi, A. M., Maroto, C. G., Rodriguez-Gutierrez, M. E., Appiah, M., Ignat, A.-D., Mobayen, G., Page, T. H., & McKinnon, T. A. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.024 · Cited by 7
American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma
Glavey, S. V., & Ghobrial, I. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1029449 · Cited by 7
“, t [4;14] with FGFR3), which can be incorporated into a predictive score of outcome allowing greater prognostic discrimination useful for identifying high-risk populations [21].”
BackgroundAlternative metrics for assessing clinical benefit with immunotherapy in oncology
Chan, E., Quinn, C., Hirji, I., Hillengaß, J., Anderson, K. C., Oukessou, A., & Davis, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1343774 · Cited by 7
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma
Vandross, A. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.002 · Cited by 7
Maruyama, D., Tobinai, K., Chou, T., Taniwaki, M., Shumiya, Y., & Iida, S. (2018) · Cancer Science · doi:10.1111/cas.13753 · Cited by 7
Kobayashi, T., Miura, M., Abumiya, M., Akamine, Y., Ito, F., & Takahashi, N. (2019) · Medical Oncology · doi:10.1007/s12032-019-1280-2 · Cited by 7
Jung, J., Choi, Y. S., Lee, J. H., Lee, W. S., Kim, S., Park, Y., Lee, S.-S., Do, Y. R., Jo, J.-C., Lee, J., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02869-y · Cited by 7
Shimura, M., Nomura, S., Wakabayashi, M., Maruo, K., & Gosho, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8633 · Cited by 7
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Premkumar, V. J., Bhutani, D., & Lentzsch, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.023 · Cited by 7
Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma
Barth, P. M., Giri, S., Reagan, J. L., & Olszewski, A. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25996 · Cited by 8
Mohyuddin, G. R., Hampton, J., Aziz, M., Khuder, S., Malik, S. U., McClune, B. L., & Abdallah, A.-O. A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.03.006 · Cited by 9
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
Pantani, L., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., Rocchi, S., Martello, M., Rizzello, I., Terragna, C., Zamagni, E., et al. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1127754 · Cited by 7
“Of note, the incidence of anygrade peripheral neuropathy was 17% in both groups of patients [19].”
BackgroundInfluentialTreatment of relapsed multiple myeloma.
Stewart, A. K., & Palumbo, A. (2015) · PubMed · doi:10.1056/nejmc1501348 · Cited by 6
Kegyes, D., Moisoiu, V., Constantinescu, C. S., Tănase, A., Ghiaur, G., Einsele, H., Tomuleasa, C., Lazarus, H. M., & Gale, R. P. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101254 · Cited by 7
Mingrone, G., Astarita, A., Colomba, A., Catarinella, C., Cesareo, M., Airale, L., Paladino, A., Leone, D., Vallelonga, F., Bringhen, S., et al. (2023) · Cancers · doi:10.3390/cancers15041149 · Cited by 6
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
Squifflet, P., Michiels, S., Siegel, D. S. D., Vij, R., Jagannath, S., Saad, E. D., Rajangam, K. L., Ro, S. K., & Buyse, M. E. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.09.005 · Cited by 6
Self-citationŠtork, M., SEVCIKOVA, S., Adam, Z., Krejčí, M., Sandecká, V., Král, Z., Brožová, L., Velichová, R., & Pour, L. (2018) · Neoplasma · doi:10.4149/neo_2018_170519n363 · Cited by 6
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Richter, J. R., & Jagannath, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.09.003 · Cited by 6
Hemodynamic Considerations in the Pathophysiology of Peripheral Neuropathy
Smith, D. I., Tran, H. T., & Poku, J. W. (2018) · InTech eBooks · doi:10.5772/intechopen.75872 · Cited by 6
“proteasome inhibitors, carfilzomib and ixazomib, have a lower incidence of CIPN compared to bortezomib [81, 82].”
BackgroundAtherosclerosis, Ischemia, and Anticancer Drugs
Singh, S., & Singh, K. (2021) · Heart Views · doi:10.4103/heartviews.heartviews_45_20 · Cited by 6
“1%, respectively.[94] Limited evidence from animal studies suggests an endothelium-dependent mechanism by which carfilzomib induces coronary vasospasm or lack of dilation contributing to ischemia.”
BackgroundMyocardial Dysfunction in Patients with Cancer
Koutroumpakis, E., Agrawal, N., Palaskas, N. L., Abe, J., Iliescu, C., Yusuf, S. W., & Deswal, A. M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.011 · Cited by 6
Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Liu, Z., Yang, C., Liu, X., Xu, X., Zhao, X., & Fu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1169541 · Cited by 8
“ASPIRE (NCT01080391) study showed that combining carfilzomib with Lenalidomide and dexamethasone demonstrated the higher rates of overall response and improved PFS and 2-year overall survival (77).”
BackgroundAilawadhi, S., Cheng, M., Cherepanov, D., DerSarkissian, M., Stull, D. M., Hilts, A., Chun, J., Duh, M. S., & Sanchez, L. J. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101078 · Cited by 6
Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
Peng, Y., Zhou, Y., Shu, K., Xu, J., & Zhong, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396378 · Cited by 6
High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges
Muchtar, E., Magen, H., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1233540 · Cited by 6
“While the triplet combination showed a PFS advantage over the doublet in standard-risk patients, a difference in high-risk patients was not evident, possibly owing to small sample size.[89] Ixazomib in combination with lenalidomide and dexamethasone was compared in a phase 3 placebocontrolled trial with lenalidomide a…”
BackgroundUpdated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras, P., Bargetzi, M. J., Betticher, D. C., Driessen, C., Duchosal, M. A., Heim, D. A., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20031 · Cited by 6
Shah, N. D., Sussman, M., Crivera, C., Valluri, S., Benner, J., & Jagannath, S. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01012-x · Cited by 6
“For the trials that did not report exposure or refractory status, the studied patient populations included newly diagnosed MM and MM that was relapsed or refractory to one to three prior lines of therapy [29, 30, 33, 35].”
BackgroundMajer, I. M., Kroep, S., Maroun, R., Williams, C., Klijn, S. L., & Palmer, S. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.011 · Cited by 6
Huo, J., Huang, Y., Zheng, Z. Y., Tay, X. N., Mahfut, F. B., Zhang, W., Lam, K., Yang, Y., & Xu, S. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac012 · Cited by 6
Mikulski, D., Robak, P. J., Ryżewska, W., Stańczak, K., Kościelny, K., Góra‐Tybor, J., & Robak, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195908 · Cited by 6
Bhutani, M., Foureau, D., Robinson, M. M., Guo, F., Fesenkova, K., Atrash, S., Paul, B. A., Varga, C., Friend, R. N., Pineda‐Roman, M., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.016 · Cited by 7
Turner, R., Quach, H., Horvath, N., Kerridge, I., Lee, E., Morris, E., Kalff, A., Khong, T. T., Reynolds, J., & Spencer, A. G. (2023) · British Journal of Haematology · doi:10.1111/bjh.18914 · Cited by 6
LeBlanc, T. W., Howson, A., Turell, W., Sheldon, P., Locke, S. C., Tuchman, S. A., Gasparetto, C., Kaura, S., Khan, Z., & Abernethy, A. P. (2016) · Current Oncology · doi:10.3747/co.23.3298 · Cited by 7
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms
Sissung, T. M., Peer, C. J., Korde, N., Mailankody, S., Kazandjian, D. G., Venzon, D. J., Landgren, O., & Figg, W. D. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3323-8 · Cited by 6
“In two recent studies [8, 13], the three-drug combination resulted in a complete response in 32–62% of patients and significant improvement in median progression-free survival (PFS) over lenalidomide and dexamethasone.”
BackgroundNovel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma
Zannetti, B. A., Tacchetti, P., Pantani, L., Gamberi, B., Tosi, P., Rocchi, S., Cellini, C., Ronconi, S., Pezzi, A., Mancuso, K., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3140-5 · Cited by 6
Xu, W., Sun, X., Wang, B., & Guo, H. M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3173-9 · Cited by 6
“OS and PFS data were derived from two randomized controlled trials (RCTs) [8, 9]; pooling them resulted in superior efficacy of carfilzomib-containing combinations Fig.”
MethodRisk-Based Therapeutic Strategies
Corre, J., & Avet‐Loiseau, H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000352 · Cited by 6
Total Synthesis of Luminmycin A, a Cryptic Natural Product from Photorhabdus Luminescens
Servatius, P., Stach, T., & Kazmaier, U. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900460 · Cited by 6
A review of epidemiology and management of multiple myeloma in a resource poor country
Akinbami, A., Dosunmu, A. O., & Uche, E. I. (2018) · Annals of Tropical Pathology · doi:10.4103/atp.atp_8_18 · Cited by 6
Engelhardt, M. M., Yong, K., Bringhen, S., & Wäsch, R. (2019) · Haematologica · doi:10.3324/haematol.2019.228684 · Cited by 8
“Carfilzomib (Cfz/K) is a second-in-class, epoxyketonebased, irreversibly binding PI, which is approved in combination with dexamethasone (Kd) or lenalidomide and dexamethasone (KRd) for the treatment of relapsed/refractory MM (RRMM) patients.(12,13) The ENDEAVOR study compared Kd versus Btz plus dexamethasone (Vd) and…”
BackgroundOriol, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1744432 · Cited by 6
Self-citationNatural History and Prognostic Factors at First Relapse in Multiple Myeloma
Wang, C., Soekojo, C. Y., Mel, S. D., Ooi, M. G. M., Chen, Y., Goh, A. Z. K., Nagarajan, C., & Chng, W. J. (2020) · Cancers · doi:10.3390/cancers12071759 · Cited by 6
Lee, H. S., Kım, K., Lee, J., Yoon, S., Bang, S., Kim, J. S., Eom, H., Yoon, D. H., Lee, Y., Shin, H., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02988-6 · Cited by 6
COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
Marchetti, M., Gale, R. P., & Barosi, G. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.034 · Cited by 6
Prognostic Potential of Heart Rate and Hypertension in Multiple Myeloma Patients
Wang, J., Tang, M., Long, Y., Song, J., Chen, L., Wang, M., Li, Y., Sun, C., & Yang, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.681484 · Cited by 7
Self-citationOjo, A. S., Araoye, M. O., Ali, A. S., & Sarma, R. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01332-1 · Cited by 7
“In the ASPIRE trial, triplet regimen significantly improved the GHS/QoL domain of the EORTC QLQ-C30, without a significant worsening on other QLQ-C30 domains or patient-reported symptoms on the QLQ-MY20 [31, 32].”
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
Shabnaz, S., Nguyen, T. N., Williams, R., Rubinstein, S. M., Garrett, T. J., Tantawy, M., Fradley, M. G., Alomar, M., Shain, K. H., Baz, R., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13828 · Cited by 5
André, A., Montes, L., Roos‐Weil, D., Frenzel, L., Vignon, M., Chalopin, T., Debureaux, P.-É., Talbot, A., Farge, A., Jardin, F., et al. (2024) · HemaSphere · doi:10.1002/hem3.106 · Cited by 5
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.